NASDAQ:UROV Urovant Sciences Stock Forecast, Price & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Urovant Sciences Ltd Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $9.22 -0.13 (-1.39 %) (As of 09/25/2020 12:00 AM ET) Add Compare Share Today's Range$8.97Now: $9.22▼$9.3050-Day Range$7.67MA: $8.63▼$10.1152-Week Range$6.55Now: $9.22▼$15.98Volume26,667 shsAverage Volume75,166 shsMarket Capitalization$287.50 millionP/E RatioN/ADividend YieldN/ABeta1.31 ProfileAnalyst RatingsChartCompetitorsEarningsInsider TradesInstitutional OwnershipHeadlinesShort InterestSocial Media Urovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for urologic conditions. It is developing vibegron, an oral, once-daily, small molecule beta-3 agonist that is in Phase III trials for the treatment of overactive bladder (OAB) and OAB in men with benign prostatic hyperplasia; and in Phase IIa clinical trials for irritable bowel syndrome-associated pain. The company was formerly known as Thalavant Sciences Ltd. and changed its name to Urovant Sciences Ltd. in January 2017. The company was founded in 2016 and is based in London, the United Kingdom. Urovant Sciences Ltd. is a subsidiary of Roivant Sciences Ltd.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingUrovant Sciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $28.00, Urovant Sciences has a forecasted upside of 203.7% from its current price of $9.22.Amount of Analyst CoverageUrovant Sciences has received no research coverage in the past 90 days. Previous Next 2.0 Community Rank Outperform VotesUrovant Sciences has received 70 “outperform” votes. (Add your “outperform” vote.)Underperform VotesUrovant Sciences has received 101 “underperform” votes. (Add your “underperform” vote.)Community SentimentUrovant Sciences has received 59.06% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Urovant Sciences and other stocks. Vote “Outperform” if you believe UROV will outperform the S&P 500 over the long term. Vote “Underperform” if you believe UROV will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldUrovant Sciences does not currently pay a dividend.Dividend GrowthUrovant Sciences does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Urovant Sciences insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.70% of the stock of Urovant Sciences is held by insiders.Percentage Held by InstitutionsOnly 20.34% of the stock of Urovant Sciences is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Urovant Sciences are expected to grow in the coming year, from ($6.73) to ($5.23) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Urovant Sciences is -1.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Urovant Sciences is -1.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next Analyst Opinion: 3.5Community Rank: 2.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.23 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:UROV Previous Symbol CUSIPN/A CIKN/A Webwww.urovant.com Phone44-0-20-7400-3347Debt Debt-to-Equity RatioN/A Current Ratio2.36 Quick Ratio2.36Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($1.90) per share Price / Book-4.85Profitability EPS (Most Recent Fiscal Year)($4.71) Net Income$-146,740,000.00 Net MarginsN/A Return on Equity-6,363.46% Return on Assets-156.89%Miscellaneous Employees17 Outstanding Shares31,182,000Market Cap$287.50 million Next Earnings Date11/3/2020 (Estimated) OptionableNot Optionable $9.22 -0.13 (-1.39 %) (As of 09/25/2020 12:00 AM ET) 30 days | 90 days | 365 days | Advanced Chart Receive UROV News and Ratings via Email Sign-up to receive the latest news and ratings for UROV and its competitors with MarketBeat's FREE daily newsletter. Urovant Sciences (NASDAQ:UROV) Frequently Asked Questions How has Urovant Sciences' stock price been impacted by Coronavirus (COVID-19)? Urovant Sciences' stock was trading at $11.37 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, UROV stock has decreased by 18.9% and is now trading at $9.22. View which stocks have been most impacted by COVID-19. Do Wall Street analysts recommend investors buy shares of Urovant Sciences? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Urovant Sciences in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Urovant Sciences. When is Urovant Sciences' next earnings date? Urovant Sciences is scheduled to release its next quarterly earnings announcement on Tuesday, November 3rd 2020. View our earnings forecast for Urovant Sciences. How were Urovant Sciences' earnings last quarter? Urovant Sciences Ltd (NASDAQ:UROV) announced its earnings results on Thursday, August, 13th. The company reported ($0.99) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($1.36) by $0.37. View Urovant Sciences' earnings history. What price target have analysts set for UROV? 1 analysts have issued 1-year price targets for Urovant Sciences' stock. Their forecasts range from $28.00 to $28.00. On average, they anticipate Urovant Sciences' stock price to reach $28.00 in the next year. This suggests a possible upside of 203.7% from the stock's current price. View analysts' price targets for Urovant Sciences. Who are some of Urovant Sciences' key competitors? Some companies that are related to Urovant Sciences include Stoke Therapeutics (STOK), Arcus Biosciences (RCUS), Repare Therapeutics (RPTX), NGM Biopharmaceuticals (NGM), Legend Biotech (AMTI), Akero Therapeutics (AKRO), Karyopharm Therapeutics (KPTI), Innoviva (INVA), Kiniksa Pharmaceuticals (KNSA), Supernus Pharmaceuticals (SUPN), Esperion Therapeutics (ESPR), Nabriva Therapeutics (NBRV), Athenex (ATNX), Rhythm Pharmaceuticals (RYTM) and Phathom Pharmaceuticals (PHAT). View all competitors. What other stocks do shareholders of Urovant Sciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Urovant Sciences investors own include Fulcrum Therapeutics (FULC), Aldeyra Therapeutics (ALDX), AVEO Pharmaceuticals (AVEO), Myovant Sciences (MYOV), Provention Bio (PRVB), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), VIVUS (VVUS) and Xeris Pharmaceuticals (XERS). Who are Urovant Sciences' key executives? Urovant Sciences' management team includes the following people: Mr. Keith A. Katkin, CEO & Director (Age 48)Ms. Christine G. Ocampo, Chief Accounting Officer and Principal Financial & Accounting Officer (Age 47)Mr. Michael E. McFadden, Chief Commercial Officer of USI (Age 52)Dr. David Hovland, Sr. VP of Global Regulatory AffairsMs. Nori Ebersole, Sr. VP & Chief HR Officer of USI (Age 56) When did Urovant Sciences IPO? (UROV) raised $150 million in an initial public offering on Thursday, September 27th 2018. The company issued 10,000,000 shares at $14.00-$16.00 per share. J.P. Morgan, Jefferies and Cowen served as the underwriters for the IPO. What is Urovant Sciences' stock symbol? Urovant Sciences trades on the NASDAQ under the ticker symbol "UROV." Who are Urovant Sciences' major shareholders? Urovant Sciences' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include FMR LLC (2.29%), FMR LLC (2.29%), Alyeska Investment Group L.P. (1.99%), LVW Advisors LLC (0.12%), Personal CFO Solutions LLC (0.11%) and First Trust Advisors LP (0.05%). Company insiders that own Urovant Sciences stock include Andrew Lo, Chemical Co Ltd Sumitomo, Fund V Lp Qvt, Holdings Ltd Dexxon, Kevin Costello, Patrick Machado, Qvt Associates Gp Llc and Sciences Ltd Roivant. View institutional ownership trends for Urovant Sciences. Which major investors are selling Urovant Sciences stock? UROV stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, and FMR LLC. View insider buying and selling activity for Urovant Sciences. Which major investors are buying Urovant Sciences stock? UROV stock was bought by a variety of institutional investors in the last quarter, including Alyeska Investment Group L.P., Personal CFO Solutions LLC, Vigilare Wealth Management, LVW Advisors LLC, and First Trust Advisors LP. Company insiders that have bought Urovant Sciences stock in the last two years include Andrew Lo, Chemical Co Ltd Sumitomo, Fund V Lp Qvt, Holdings Ltd Dexxon, Kevin Costello, Patrick Machado, Qvt Associates Gp Llc, and Sciences Ltd Roivant. View insider buying and selling activity for Urovant Sciences. How do I buy shares of Urovant Sciences? Shares of UROV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Urovant Sciences' stock price today? One share of UROV stock can currently be purchased for approximately $9.22. How big of a company is Urovant Sciences? Urovant Sciences has a market capitalization of $287.50 million. The company earns $-146,740,000.00 in net income (profit) each year or ($4.71) on an earnings per share basis. Urovant Sciences employs 17 workers across the globe. What is Urovant Sciences' official website? The official website for Urovant Sciences is www.urovant.com. How can I contact Urovant Sciences? Urovant Sciences' mailing address is 11-12 STREET JAMES SQUARE SUITE 1 3RD FLOOR, LONDON X0, SW1Y 4LB. The company can be reached via phone at 44-0-20-7400-3347 or via email at [email protected] This page was last updated on 9/26/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
